Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    25-March-2001      
Issue 84 Next Update - 14:00 UTC 08:00 EST    26-March-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya The Latest On Herceptin For Metastatic Breast Cancer

24 March 2001

Data from the landmark study that earned Herceptin® approval in 1998 by the Food and Drug Administration (FDA) for the treatment of metastatic breast cancer were published in the New England Journal of Medicine on 15 March 2001.

The study shows that Herceptin increases overall response rate to treatment, slows progression of metastatic breast disease, and increases overall survival for patients given the drug along with standard chemotherapy compared to chemotherapy alone. The newly published report extends the study's followup through October 1999.

Herceptin (trastuzumab) is a monoclonal antibody designed in the laboratory that targets a genetic defect found in some cancer cells. "This is the beginning of an important new era in cancer treatment, since many more such targeted therapies are now undergoing clinical evaluation," wrote Elizabeth Eisenhauer, M.D., Queens University, in an editorial accompanying the journal article.

Current Clinical Trials of Herceptin:

Herceptin and Breast Cancer

Hereceptin and Other Cancers

Related articles on Herceptin:

Questions and Answers About Herceptin® (Trastuzumab)

Herceptin® Provides Overall Survival Benefit When Added to Chemotherapy for the Treatment of Metastatic Breast Cancer (May 15, 1999)

Two New Trials To Test Herceptin® in Non-Metastatic Breast Cancer

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 
Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.